Clinical Trial

Integrating Multimodal AI to Predict Treatment Response and Refine Risk Stratification in Esophageal Cancer （Radiogenomics-Esophagus）

Recruiting
View on ClinicalTrials.gov →
Summary
This AI-driven model leverages multimodal data-such as radiomics, pathomics, genomics, and broader multi-omics profiles-to capture complementary aspects of tumor biology and predict treatment response and prognosis.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2026-01-12; most recent amendment 2026-03-06.
Trial Details
NCT Number NCT07354295
Lead Sponsor Shu Peng
Collaborators: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, The First Affiliated Hospital of Henan University of Science and Technology, Henan Provincial People's Hospital, Zhongnan Hospital, Renmin Hospital of Wuhan University
Conditions Esophageal Cancer
Enrollment 1,500 participants
Start Date 2025-07-26
Primary Completion 2030-09-30 (estimated)
Study Completion 2030-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-10